RNA 간섭 기술 시장 : 분자 유형, 투여 경로, 전달 방법, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The RNA Interference Technology Market is projected to grow by USD 8.26 billion at a CAGR of 12.96% by 2032.

RNA interference technology is a validated gene-silencing platform that uses small interfering RNA, microRNA modulation, and related double-stranded RNA approaches to reduce disease-driving messenger RNA before harmful proteins are produced. Since the RNAi mechanism was described in 1998 and recognized with the 2006 Nobel Prize in Physiology or Medicine, the field has moved from discovery biology to approved RNAi therapeutics, agricultural biotechnology, functional genomics, and precision medicine.

Commercial momentum is supported by regulatory approvals for siRNA drugs such as patisiran, givosiran, lumasiran, inclisiran, vutrisiran, and nedosiran, which demonstrate the clinical value of RNAi for rare diseases, cardiometabolic disorders, renal and metabolic conditions, and liver-targeted indications. The market is increasingly defined by delivery innovation, especially GalNAc conjugates for hepatocyte targeting, lipid nanoparticle systems for broader tissue access, and improved oligonucleotide chemistry that enhances potency, durability, and tolerability.

Transformative Shifts in the RNAi Landscape

The RNA interference landscape is shifting from specialized rare-disease programs toward broader chronic-disease opportunities, with cardiometabolic, renal, ophthalmic, neurological, oncology, and infectious-disease pipelines gaining visibility. Durable gene silencing, infrequent dosing, and target specificity are strengthening the value proposition against conventional small molecules and monoclonal antibodies, particularly where disease biology is driven by genetically defined or previously undruggable targets.

The most transformative change is delivery. GalNAc-siRNA conjugates have reduced dosing frequency and improved liver targeting, while lipid nanoparticles, extrahepatic ligands, inhaled, intrathecal, intravitreal, and local delivery approaches are expanding the addressable target space. At the same time, regulators are demanding rigorous off-target, immunogenicity, chemistry-manufacturing-control, biodistribution, drug-drug interaction, and long-term safety evidence, making platform quality a core competitive advantage.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating RNAi discovery by improving target prioritization, siRNA sequence design, off-target prediction, toxicity screening, and delivery formulation optimization. Machine learning models trained on transcriptomic, proteomic, structural, genomic, and clinical datasets can help identify disease-relevant genes and reduce the number of low-probability candidates entering costly laboratory validation.

AI is also strengthening precision medicine strategies by supporting biomarker discovery, patient segmentation, trial enrichment, and real-world evidence analysis for RNAi therapeutics. However, AI does not replace experimental validation; high-confidence RNAi programs still require reproducible in vitro, in vivo, pharmacokinetic, pharmacodynamic, manufacturing, and clinical evidence to confirm durable silencing, target engagement, and acceptable safety profiles.

Key Regional Insights

North America remains a leading RNA interference technology hub due to the presence of major biotechnology ecosystems, FDA experience with oligonucleotide therapeutics, strong venture financing, academic medical centers, and deep clinical trial infrastructure. Europe benefits from the European Medicines Agency pathway, academic excellence, national genomic medicine initiatives, and cross-border research programs, while the European Union supports harmonized standards for advanced therapeutics, pharmacovigilance, and pharmaceutical manufacturing.

Asia-Pacific is becoming increasingly influential as China expands biopharmaceutical innovation and nucleic acid drug development, Japan supports advanced therapy adoption through mature regulatory and clinical systems, India scales contract research and manufacturing capacity, South Korea invests in biotech platforms, and Australia maintains strong early-phase clinical trial capabilities. Latin America is led by Brazil and Mexico in clinical access and research participation, while the Middle East is building genomics-led healthcare systems, especially across GCC markets. Africa shows long-term potential in infectious disease, agriculture, and public health applications of RNA interference technology, though infrastructure, affordability, cold-chain logistics, and specialist access constraints remain material.

Key Group Insights

The G7 countries are central to RNAi commercialization because they combine mature regulators, reimbursement systems, intellectual property protection, advanced clinical networks, and established pharmaceutical manufacturing standards. The European Union strengthens consistency through coordinated regulatory oversight, multinational research funding, health technology assessment collaboration, and quality frameworks for medicines, while NATO-aligned markets add resilience priorities related to biomanufacturing, health security, strategic stockpiles, and supply chain continuity.

BRICS markets are strategically important for future RNAi scale because China, India, and Brazil offer large patient populations, expanding biotech investment, and growing manufacturing capabilities, while Russia and South Africa contribute scientific capacity under more variable access conditions. ASEAN is gaining relevance through Singapore-led biomedical research and growing clinical activity in Thailand, Malaysia, Vietnam, the Philippines, and Indonesia. The GCC is advancing precision medicine through national genomics programs, specialty care investment, digital health infrastructure, and partnerships that support access to advanced RNAi therapeutics.

Key Country Insights

The United States leads global RNA interference technology development through FDA-approved siRNA therapeutics, major biotechnology clusters, NIH-backed research, specialized clinical investigators, and capital access. Canada contributes strong academic science, publicly supported genomics research, and clinical research networks, while Mexico is an important access and trial market in North America. Brazil anchors Latin American opportunity through its healthcare scale, public research institutions, specialist hospitals, and experience in complex biologics access.

In Europe, the United Kingdom, Germany, France, Italy, and Spain support RNAi adoption through advanced clinical centers, established pharmaceutical ecosystems, rare disease networks, and payer evaluation systems, while Russia maintains scientific capabilities but faces market-access and geopolitical constraints. China is rapidly expanding RNAi pipelines, clinical trial activity, and biomanufacturing capacity; India is strengthening cost-efficient research, production, and contract development capabilities; Japan emphasizes high-quality clinical translation, regulatory rigor, and specialty medicine adoption; Australia supports early-phase trials through efficient clinical infrastructure; and South Korea is building competitive biotech platforms in nucleic acid medicines, precision medicine, and advanced manufacturing.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize delivery platforms that extend RNAi beyond the liver while maintaining validated safety, reproducible manufacturing, and clear pharmacodynamic evidence. Organizations should invest in GalNAc, lipid nanoparticles, local delivery, ligand discovery, endosomal escape technologies, and scalable oligonucleotide synthesis to protect differentiation as competition increases.

Strategic success will depend on disciplined indication selection, payer-ready value evidence, and regulatory alignment from early development. Leaders should combine AI-enabled discovery with wet-lab validation, build regional clinical partnerships, secure resilient raw-material and oligonucleotide supply, strengthen quality systems, and prepare market-access strategies that demonstrate durable outcomes, reduced dosing burden, and measurable healthcare-system value.

Research Methodology

A structured methodology combining secondary research, primary interviews, data triangulation, and expert validation supports the assessment of RNA interference technology. Inputs include regulatory approvals, clinical trial registries, scientific literature, patent activity, company disclosures, government health data, reimbursement signals, public funding initiatives, and biopharmaceutical investment trends relevant to RNA interference technology.

The analysis evaluates technology maturity, delivery platforms, therapeutic pipelines, regional adoption, competitive positioning, regulatory requirements, manufacturing readiness, and commercialization barriers. Findings are cross-verified against public agency records, peer-reviewed evidence, clinical databases, and market participants' perspectives to ensure that conclusions are data-backed, current, and suitable for decision-making, without relying on market sizing, share estimates, or forecasts.

Conclusion

RNA interference technology has transitioned from a breakthrough biological discovery into a clinically validated modality with expanding commercial relevance. Approved siRNA therapeutics have confirmed that targeted gene silencing can deliver durable benefits, while advances in delivery systems are opening new disease areas and broader patient populations.

The next phase of leadership will be determined by extrahepatic delivery, AI-supported discovery, manufacturing scalability, regulatory, safety monitoring, and evidence-based reimbursement. Organizations that integrate scientific rigor with a regional access strategy will be best positioned to capture value in RNAi therapeutics, functional genomics, agricultural biotechnology, and next-generation precision medicine.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. RNA Interference Technology Market, by Molecule Type

• 7.1. MicroRNA (miRNA)
• 7.2. Short Hairpin RNA (shRNA)
  • 7.2.1. Non-Viral Delivery shRNA
  • 7.2.2. Viral Delivery shRNA
• 7.3. Small Interfering RNA (siRNA)
  • 7.3.1. Conjugated siRNA
  • 7.3.2. Non-Conjugated siRNA

8. RNA Interference Technology Market, by Route Of Administration

• 8.1. Intramuscular (IM) Injection
• 8.2. Intrathecal (IT) Administration
• 8.3. Intravenous (IV) Injection

9. RNA Interference Technology Market, by Delivery Method

• 9.1. Direct Naked RNAi Delivery
• 9.2. Exosome-Based RNAi Therapy
• 9.3. Nanoparticle-Based Delivery
• 9.4. Viral Vector-Based Delivery

10. RNA Interference Technology Market, by Application

• 10.1. Drug Discovery
  • 10.1.1. Lead Optimization
  • 10.1.2. Target Identification
• 10.2. Research & Development
  • 10.2.1. Gene Function Studies
  • 10.2.2. Pathway Analysis
• 10.3. Therapeutics

11. RNA Interference Technology Market, by End-User

• 11.1. Contract Research Organizations
• 11.2. Hospitals & Clinics
• 11.3. Pharmaceutical & Biotechnology Companies

12. RNA Interference Technology Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. RNA Interference Technology Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. RNA Interference Technology Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. ADARx Pharmaceuticals Inc
• 16.2. Alnylam Pharmaceuticals Inc
• 16.3. Arbutus Biopharma Corporation
• 16.4. Arcturus Therapeutics Holdings Inc
• 16.5. Arrowhead Pharmaceuticals Inc
• 16.6. AstraZeneca PLC
• 16.7. Avidity Biosciences Inc
• 16.8. Benitec Biopharma Inc
• 16.9. BioNTech SE
• 16.10. City Therapeutics Inc
• 16.11. Genevant Sciences Ltd
• 16.12. Intellia Therapeutics Inc
• 16.13. Ionis Pharmaceuticals Inc
• 16.14. Moderna Inc
• 16.15. Novartis AG
• 16.16. Novo Nordisk A/S
• 16.17. OliX Pharmaceuticals Inc
• 16.18. Phio Pharmaceuticals Corp
• 16.19. ProQR Therapeutics NV
• 16.20. Roche Holding AG
• 16.21. Sanofi SA
• 16.22. Sarepta Therapeutics Inc
• 16.23. Silence Therapeutics PLC
• 16.24. Sirnaomics Inc
• 16.25. Suzhou Ribo Life Science Co., Ltd
• 16.26. Vir Biotechnology Inc
• 16.27. Wave Life Sciences Ltd